Working… Menu

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03023904
Recruitment Status : Withdrawn (Research cancelled)
First Posted : January 18, 2017
Last Update Posted : April 25, 2018
Information provided by (Responsible Party):
Douglas Johnson, Vanderbilt-Ingram Cancer Center

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : July 30, 2019
Estimated Study Completion Date : July 30, 2020